NUGALVIQ
Dead / Abandoned — Abandoned — no statement of use filed (as of 24 Nov 2025)
What this means for you
This application is over — abandoned 24 Nov 2025. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97072078
- Mark type
- Design + words
- Filed
- 13 Oct 2021
- Published for opposition
- 23 Aug 2022
- Abandoned
- 24 Nov 2025
- Attorney of record
- Anna Kurian Shaw
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for treatment of rare orphan diseases; Pharmaceutical preparations for treatment of diseases that impact sugar and glucose metabolism; Pharmaceutical preparations for inhibiting aldose reductase; Pharmaceutical preparations for treatment of galactosemia, sorbitol dehydrogenase (SORD) deficiency and PMM2-congenital disorder of glycosylation (PMM2-CDG)
Owner
- Applied Therapeutics, Inc., New York, NY, US
- Applied Therapeutics, Inc., New York, NY, US
Prosecution history
- 24 Nov 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 24 Nov 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 24 Nov 2025 — ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
- 24 Nov 2025 — ABANDONMENT - NO USE STATEMENT FILED
- 10 Jul 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 10 Jul 2025 — SOU EXTENSION 5 GRANTED
- 18 Mar 2025 — SOU EXTENSION 5 FILED
- 10 Jul 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 18 Mar 2025 — SOU TEAS EXTENSION RECEIVED
- 07 Oct 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 07 Oct 2024 — SOU EXTENSION 4 GRANTED
- 07 Oct 2024 — SOU EXTENSION 4 FILED
- 07 Oct 2024 — SOU TEAS EXTENSION RECEIVED
- 23 Mar 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 22 Mar 2024 — SOU EXTENSION 3 GRANTED